Apimeds Pharmaceuticals US, Inc. (APUS) — Long-term Investment Intensity
Apimeds Pharmaceuticals US, Inc. (APUS) has a Long-term Investment Intensity of 90.5% as of March 2026. Long-term investments of $127.82 Million represent 90.5% of total assets of $141.22 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See Apimeds Pharmaceuticals US, Inc. (APUS) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Apimeds Pharmaceuticals US, Inc. Long-term Investment Intensity (2025–2025)
This chart shows how Apimeds Pharmaceuticals US, Inc.'s Long-term Investment Intensity has evolved across 1 annual periods from 2025 to 2025. As of March 2026, the intensity stands at 90.5%, reflecting long-term investments of $127.82 Million against total assets of $141.22 Million USD. See operational self-sufficiency of Apimeds Pharmaceuticals US, Inc. to measure how many days the company can operate on defensive assets alone.
Annual Long-term Investment Intensity for Apimeds Pharmaceuticals US, Inc. (2025–2025)
The table below presents the year-by-year Long-term Investment Intensity for Apimeds Pharmaceuticals US, Inc. from 2025 to 2025, covering 1 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see APUS total asset value.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 91.3% | $149.89 Million | $164.18 Million | — |